Mechanistic science in cardiovascular-oncology: the way forward to maximise anti-cancer drug effects and minimise cardiovascular toxicity

Clin Sci (Lond). 2021 Dec 10;135(23):2661-2663. doi: 10.1042/CS20210986.

Abstract

Dramatic improvements in cancer survival have arisen because of the rapid development of novel anti-cancer therapies. The potential for cardiovascular toxicity associated with these drugs often reflects overlap between pathogenic cancer mechanisms and physiological pathways required for normal cardiovascular function. Clinical Science has, therefore, compiled a themed collection on Cardiovascular-Oncology. This collection examines the intersection between cancer treatments and their potentially harmful cardiovascular effects. By defining the mechanisms underlying unwanted cardiovascular effects of anti-cancer therapies, cardioprotective strategies can be developed. Only by doing so, will patients be able to achieve optimal cancer treatment at the minimum cost to cardiovascular health.

Keywords: cancer; cardiovascular disease; pharmacology.

Publication types

  • Editorial
  • Introductory Journal Article
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anthracyclines / adverse effects
  • Antineoplastic Agents / adverse effects*
  • Cardiotoxicity / etiology
  • Cardiotoxicity / prevention & control*
  • Humans
  • Immunotherapy
  • Molecular Targeted Therapy
  • Neoplasms / drug therapy*

Substances

  • Anthracyclines
  • Antineoplastic Agents